Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(170 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(78 products)
- Syk(38 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1414 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
YH-306
CAS:<p>YH-306 (TRV055 acetate ) is a modulator of the FAK signaling pathway that acts by suppressing colorectal tumor growth and metastasis.</p>Formula:C19H18N2O2Purity:98.06%Color and Shape:SolidMolecular weight:306.36Multi-kinase-IN-2
CAS:<p>Orally active Multi-kinase-IN-2 blocks angiokinases including VEGFR, PDGFR, FGFR, and more, reducing AKT/ERK phosphorylation and promoting apoptosis.</p>Formula:C34H35N5O3Color and Shape:SolidMolecular weight:561.67ER 27319 maleate
CAS:<p>Selective inhibitor of Syk kinase</p>Formula:C22H24N2O5Purity:98%Color and Shape:SolidMolecular weight:396.44Momelotinib Mesylate
CAS:<p>Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.</p>Formula:C24H26N6O5SPurity:98%Color and Shape:SolidMolecular weight:510.57TL02-59 dihydrochloride
CAS:<p>TL02-59 dihydrochloride is an orally active inhibitor of Src-family kinase Fgr (IC50: 0.03 nM).</p>Formula:C32H36Cl2F3N5O4Purity:98%Color and Shape:SolidMolecular weight:682.56LRRK2/NUAK1/TYK2-IN-1
CAS:<p>LRRK2/NUAK1/TYK2-IN-1 inhibits LRRK2, TYK2, NUAK1 with IC50 < 10 nM, useful in autoimmune research.</p>Formula:C20H11F3N6Color and Shape:SolidMolecular weight:392.34EGFR-IN-28
CAS:<p>EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .</p>Formula:C31H39BrN10O3SColor and Shape:SolidMolecular weight:711.68AP 24149
CAS:<p>AP 24149, a potent dual inhibitor targeting Src and Abl, exhibits IC50 values of 9.1 nM for Src and 3.6 nM for Abl, respectively.</p>Formula:C23H24N5OPColor and Shape:SolidMolecular weight:417.44FGFR-IN-9
<p>FGFR-IN-9: oral FGFR inhibitor, IC50: 17.1 nM (FGFR4 WT), 29.6 (FGFR3), 30.7 (V550L), 46.7 (FGFR2), 64.3 nM (FGFR1).</p>Formula:C25H28N6O3SColor and Shape:SolidMolecular weight:492.59GW837016X
CAS:<p>GW837016X, also known as NEU-391, is a potent inhibitor of protozoan parasite proliferation.</p>Formula:C25H20ClFN4OSColor and Shape:SolidMolecular weight:478.97TG53
CAS:<p>TG53 is a tissue transglutaminase (TG2) and fibronectin (FN) protein-protein interaction inhibitor.</p>Formula:C21H22ClN5O2Purity:98%Color and Shape:SolidMolecular weight:411.88Thi-DPPY
CAS:<p>Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.</p>Formula:C28H28ClN5O4SColor and Shape:SolidMolecular weight:566.07CAY10717
CAS:<p>CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.</p>Formula:C29H25F3N6O3Color and Shape:SolidMolecular weight:562.54Peficitinib hydrobromide
CAS:<p>Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.</p>Formula:C18H23BrN4O2Color and Shape:SolidMolecular weight:407.312EGFR-IN-53
CAS:<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Formula:C14H13N3O2SColor and Shape:SolidMolecular weight:287.34FGFR-IN-3
CAS:<p>FGFR-IN-3: potent, oral FGFR modulator, BBB-penetrating, neuroprotective, potential in neurodegeneration study.</p>Formula:C18H27F2N5O2Color and Shape:SolidMolecular weight:383.44Derazantinib Racemate
CAS:<p>Derazantinib Racemate is an oral ATP competitive kinase inhibitor targeting FGFR1/2/3 (IC50s: 4.5/1.8/4.5 nM).</p>Formula:C29H29FN4OPurity:98%Color and Shape:SolidMolecular weight:468.57EGFR-IN-75
<p>EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.</p>Formula:C10H6N6S2Color and Shape:SolidMolecular weight:274.32EGFR-IN-40
CAS:<p>EGFR-IN-40 (compound 3z) is a potent inhibitor of BTK (IC50: 1.2 nM), EGFR (IC50: 5.3 nM) and ITK (IC50: 46.1 nM).</p>Formula:C23H20N6O3Color and Shape:SolidMolecular weight:428.44(E/Z)-AG490
CAS:<p>(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.</p>Formula:C17H14N2O3Color and Shape:SolidMolecular weight:294.3FLT3-IN-11
CAS:<p>FLT3-IN-11, an oral FLT3 kinase inhibitor: potent, selective, IC50 - wild-type 7.22 nM, FLT3-D835Y 4.95 nM, anti-AML IC50 3.2 nM for MV4-11.</p>Formula:C20H25F3N6OColor and Shape:SolidMolecular weight:422.45FLT3/CDK4-IN-1
CAS:<p>FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.</p>Formula:C25H28F2N8Color and Shape:SolidMolecular weight:478.54PD 173955-Analog1
CAS:<p>PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.</p>Formula:C21H14Cl2N4O3Color and Shape:SolidMolecular weight:441.27AhR modulator-1
CAS:<p>AhR modulator-1: orally active, selective, inhibits metastasis and prostatic VEGF, anti-estrogenic in rat uterus.</p>Formula:C13H7Cl3OPurity:98%Color and Shape:SolidMolecular weight:285.55FAK-IN-5
CAS:<p>FAK-IN-5 is a FAK signaling inhibitor that induces apoptosis and autophagy.</p>Formula:C29H29ClF3N3O4Color and Shape:SolidMolecular weight:576.01Povorcitinib
CAS:<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>Formula:C23H22F5N7OColor and Shape:SolidMolecular weight:507.469JS25
CAS:<p>JS25, a selective BTK inhibitor, inactivates it with a 5.8 nM IC50, halts cancer cell growth, induces death, and aids against lymphoma.</p>Formula:C29H24N4O4SColor and Shape:SolidMolecular weight:524.59(2R,5S)-Ritlecitinib
CAS:<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>Formula:C15H19N5OColor and Shape:SolidMolecular weight:285.34QL-X-138
CAS:<p>QL-X-138: Dual BTK/MNK inhibitor; covalent to BTK, IC50=9.4 nM; non-covalent to MNK1/2, IC50=107.4/26 nM; dengue virus 2 IC50=3.5 μM; for B-cell malignancies.</p>Formula:C25H19N5O2Purity:98.82% - 99.50%Color and Shape:SolidMolecular weight:421.45TUL01101
CAS:<p>TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.</p>Formula:C22H25F2N5O2Color and Shape:SolidMolecular weight:429.46HP1328
CAS:<p>HP1328: potent FLT3/ITD inhibitor, reduces leukemia, extends survival in mice, belongs to benzoimidazole family.</p>Formula:C23H23N3O3Color and Shape:SolidMolecular weight:389.45FLT3-IN-17
CAS:<p>FLT3-IN-17: FAK inhibitor, IC50 of 12 nM; blocks CYPs, FLT3 mutants; IC50 <0.5 nM for D835Y in cancer studies.</p>Formula:C23H24N6O2S2Color and Shape:SolidMolecular weight:480.61c-Met-IN-11
CAS:<p>c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).</p>Formula:C30H20F2N4O3Color and Shape:SolidMolecular weight:522.5LS-104
CAS:<p>LS-104 is a JAK2 inhibitor.</p>Formula:C19H16N2O3Color and Shape:SolidMolecular weight:320.34BLK degrader 1
CAS:<p>BLK degrader 1 is a BLK degrader with anticancer activity for cancer research.</p>Formula:C32H25F3N6O2Purity:99.22% - 99.24%Color and Shape:SolidMolecular weight:582.58VEGFR-2-IN-28
CAS:<p>VEGFR-2-IN-28 is a potent inhibitor of VEGFR-2 (IC50: 0.83 μM). VEGFR-2-IN-28 induces apoptosis and exhibits antitumor effects.</p>Formula:C26H17N7O7Color and Shape:SolidMolecular weight:539.46FGFR3-IN-5
CAS:<p>FGFR3-IN-5: potent, selective FGFR3 inhibitor. IC50: 3 nM FGFR3, 44 nM FGFR2, 289 nM FGFR1. For cancer research.</p>Formula:C24H24FN7O3Color and Shape:SolidMolecular weight:477.49S116836
CAS:<p>S116836 is a tyrosine kinase inhibitor.</p>Formula:C27H21F3N6OPurity:98%Color and Shape:SolidMolecular weight:502.49FAK inhibitor 5
CAS:<p>FAK inhibitor 5 is a novel allosteric FAK inhibitor, with IC50 values in the low micromolar range.</p>Formula:C20H21N3O2SPurity:98%Color and Shape:SolidMolecular weight:367.46PDGFRα/FLT3-ITD-IN-2
CAS:<p>PDGFRα/FLT3-ITD-IN-2 is a potent inhibitor of PDGFRα (IC50>20 μM) and FLT3 (IC50: 0.004 μM).</p>Formula:C28H41N9OColor and Shape:SolidMolecular weight:519.68PD173952
CAS:<p>PD173952 is a Src kinase and Myt1 inhibitor with antitumor activity, inhibits Lyn, Abl and Csk, and induces Bcr-Abl-dependent hematopoietic cell apoptosis.</p>Formula:C24H21Cl2N5O2Purity:99.5%Color and Shape:SolidMolecular weight:482.36Adhesamine
CAS:<p>Adhesamine, a dumbbell molecule, enhances cell adhesion, growth, neuron differentiation, and survival via MAPK/FAK.</p>Formula:C24H32Cl4N8O2S2Color and Shape:SolidMolecular weight:670.51EGFR/HER2/TS-IN-2
CAS:<p>EGFR/HER2/TS-IN-2: Strong EGFR, HER2 & TS inhibitor; EGFR IC50=0.173μM, HER2 IC50=0.125μM, TS IC50=1.12μM; kills MDA-MB-231 cells (IC50=1.69μM).</p>Formula:C26H21N7OS2Color and Shape:SolidMolecular weight:511.62BSc5371
CAS:<p>BSc5371: Irreversible FLT3 inhibitor; Kds 0.83-5.8 nM for various FLT3 mutants including wild type.</p>Formula:C24H31N5O4SPurity:98%Color and Shape:SolidMolecular weight:485.6VEGFR-2/BRAF-IN-2
<p>VEGFR-2/BRAF-IN-2 inhibits VEGFR-2, BRAF V600E, BRAF WT (IC50: 0.111/0.089/0.071 µM); induces G1 arrest and apoptosis.</p>Formula:C26H21ClF3N5O3S2Color and Shape:SolidMolecular weight:608.05MAX-40279 hydrochloride
CAS:<p>MAX-40279 HCl: potent FLT3/FGFR inhibitor; potential in AML research.</p>Formula:C22H24ClFN6OSColor and Shape:SolidMolecular weight:474.98Con B-1
CAS:<p>ConB-1 is a potent and selective ALK inhibitor with low toxicity to normal cells .</p>Formula:C38H52ClN7O6SColor and Shape:SolidMolecular weight:770.38PDZ1i
CAS:<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Formula:C28H26N8O4Color and Shape:SolidMolecular weight:538.56BIBX 1382 Dihydrochloride
CAS:<p>BIBX 1382 Dihydrochloride blocks Lassa/Ebola entry, aids in studying virus-host interactions, and hints at kinase targets for therapy.</p>Formula:C18H21Cl3FN7Color and Shape:SolidMolecular weight:460.76BCR-ABL1-IN-1
CAS:<p>BCR-ABL1-IN-1: potent, orally active ABL kinase inhibitor with high specificity, promising for CNS research.</p>Formula:C18H12F3N3O2Color and Shape:SolidMolecular weight:359.3EGFR/HER2/CDK9-IN-1
CAS:<p>EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.</p>Formula:C23H21N3O3S2Color and Shape:SolidMolecular weight:451.56MAX-40279
CAS:<p>MAX-40279 is a potent, dual FLT3 kinase and FGFR kinase inhibitor. MAX-40279 has potential for acute myeloid leukemia (AML) studies.</p>Formula:C22H23FN6OSColor and Shape:SolidMolecular weight:438.52EGFR/HER2/TS-IN-1
CAS:<p>EGFR/HER2/TS-IN-1 inhibits EGFR (0.203 μM), HER2 (0.088 μM), TS (0.168 μM), and induces apoptosis in MCF7 cells.</p>Formula:C24H15N5O4S2Color and Shape:SolidMolecular weight:501.54LDC0496
CAS:<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Formula:C32H35N5O3Color and Shape:SolidMolecular weight:537.65AFG210
CAS:<p>AFG210 is a novel first-generation “type II” FLT3 inhibitor.</p>Formula:C19H14F3N3O2Color and Shape:SolidMolecular weight:373.33VEGFR-2-IN-23
CAS:<p>VEGFR-2-IN-23 (11b) is a potent VEGFR-2 inhibitor with an IC50 of 0.34 nM, exhibits antitumor effects, and causes G1 cell cycle arrest.</p>Formula:C22H15N5O2Color and Shape:SolidMolecular weight:381.39Lck-IN-1
CAS:<p>Lck-IN-1 is a potent inhibitor of lymphocyte protein tyrosine kinase (Lck) [1].</p>Formula:C14H15N5Color and Shape:SolidMolecular weight:253.3AGL 2043
CAS:<p>AGL 2043 is a potent, reversible, ATP-competitive inhibitor of type III receptor tyrosine kinases.</p>Formula:C15H12N4SColor and Shape:SolidMolecular weight:280.35α7 nAchR-JAK2-STAT3 agonist 1
CAS:<p>α7 nAchR-JAK2-STAT3 agonist 1 is a potent inhibitor of the α7 nAchR-JAK2-STAT3 pathway that acts on nitric oxide (NO) (IC50: 0.32 μM).</p>Formula:C25H30O6Color and Shape:SolidMolecular weight:426.5BCR-ABL-IN-5
CAS:<p>BCR-ABL-IN-5: Bcr-Abl kinase inhibitor, IC50: Bcr-AblWT 0.014 μM, Bcr-AblT315I 0.45 μM; anti-leukemia cell growth.</p>Formula:C25H21Cl2N5O2Color and Shape:SolidMolecular weight:494.37Luxeptinib
CAS:<p>Luxeptinib (CG-806) is an oral, non-covalent pan-FLT3/BTK inhibitor for acute myeloid leukemia.</p>Formula:C25H17F4N5O2Color and Shape:SolidMolecular weight:495.43GDC-4379
CAS:<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>Formula:C21H18ClF2N7O3Color and Shape:SolidMolecular weight:489.86PHA-680626
CAS:<p>PHA-680626 is a PLK inhibitor, effective on resistant leukemia cells, with IC50: Plk1 (0.53 μM), Plk2 (0.07 μM), Plk3 (1.61 μM).</p>Formula:C23H26N6O2SColor and Shape:SolidMolecular weight:450.56EGFR-IN-63
CAS:<p>EGFR- IN-63 is an EGFR inhibitor with an IC50 value of 0.096 μM. EGFR- IN-63 exhibited anticancer effects on MCF-7 cells (IC50: 2.49 μM).</p>Formula:C20H12BrN5SColor and Shape:SolidMolecular weight:434.31BTK-IN-22
CAS:<p>BTK-IN-22 is a selective BTK inhibitor with IC50 of 0.9 nM; also targets BLX, BMX (IC50s: 1.4, 1.2 nM); better selectivity than Ibrutinib.</p>Formula:C26H26N6O2Color and Shape:SolidMolecular weight:454.52pan-HER-IN-2
CAS:<p>pan-HER-IN-2 (Compound C6) is an orally active, reversible, broad-spectrum HER inhibitor that acts on EGFR (IC50: 0.72 nM), HER4 (IC50: 2.0 nM), EGFRT790M (IC50</p>Formula:C19H15BrClN5OColor and Shape:SolidMolecular weight:444.71EGFR/C797S-IN-1
CAS:<p>EGFR/C797S-IN-1: Potent EGFR-C797S inhibitor, IC50 of 0.128 µM, dose-dependent p-EGFR suppression, anti-tumor properties.</p>Formula:C28H30N4O3Color and Shape:SolidMolecular weight:470.56PDGFRα/FLT3-ITD-IN-3
CAS:<p>PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα (IC50: 0.153 μM), FLT3 (IC50: 0.004 μM) and PDGFRα/FLT3-ITD-IN-3 has the potential to be</p>Formula:C26H39N9Color and Shape:SolidMolecular weight:477.65CHMFL-ABL-053
CAS:<p>CHMFL-ABL-053: potent, selective BCR-ABL/SRC/p38 inhibitor (IC50: 70/90/62 nM). Orally available, potential CML drug.</p>Formula:C28H26F3N7O2Color and Shape:SolidMolecular weight:549.55EGFR/HER2-IN-9
CAS:<p>EGFR/HER2-IN-9, a compound inhibiting both EGFR and HER2, demonstrates potency with IC50 values of 3.2 nM for EGFR, 14 nM for HER2, and 8.3 nM against the EGFR</p>Formula:C25H25ClFN5O4Color and Shape:SolidMolecular weight:513.95Ebselen oxide
CAS:<p>Ebselen oxide (EB-2) is a HER2 inhibitor with antibacterial and antifungal activity and has shown cytoprotective effects against HN2 in vitro.</p>Formula:C13H9NO2SePurity:98%Color and Shape:SolidMolecular weight:290.18SMU-B
CAS:<p>SMU-B is a well-tolerated c-Met/ALK dual inhibitor.</p>Formula:C26H25Cl2FN4O2Purity:98%Color and Shape:SolidMolecular weight:515.41BTK-IN-23
CAS:<p>BTK-IN-23: BTK inhibitor, IC50=12.8 nM; also blocks BLX (35.6 nM), BMX (5.7 nM); better selectivity than Ibrutinib.</p>Formula:C27H28N6O2Color and Shape:SolidMolecular weight:468.55EGFR/CDK2-IN-1
CAS:<p>EGFR/CDK2-IN-1, an inhibitor of both EGFR and CDK2, demonstrates effective cytotoxicity towards MCF7 and HepG2 cells, suggesting its potential application in</p>Formula:C19H12BrClO2Color and Shape:SolidMolecular weight:387.65Ficonalkib
CAS:<p>Ficonalkib is a potent antineoplastic agent that inhibits the Anaplastic Lymphoma Kinase (ALK) tyrosine kinase receptor.</p>Formula:C29H39N7O3SColor and Shape:SolidMolecular weight:565.73PHM16
CAS:<p>PHM16 is an ATP competitive FAK and FGFR2 inhibitor.</p>Formula:C20H22N6O4Purity:98%Color and Shape:SolidMolecular weight:410.43BI-1622
CAS:<p>BI-1622, an oral HER2 inhibitor, IC50: 7 nM, >25x selectivity over EGFR, shows effective in vivo antitumor activity.</p>Formula:C26H24N10O2Color and Shape:SolidMolecular weight:508.53ProMMP-9 inhibitor-3c
CAS:<p>ProMMP-9 inhibitor-3c hinders MMP-9 homodimers, blocks proMMP-9/α4β1 integrin/CD44 binding, and detaches EGFR.</p>Formula:C18H20FN3O2SColor and Shape:SolidMolecular weight:361.43EGFR-IN-57
CAS:<p>EGFR-IN-57: potent EGFR-TK blocker, IC50 0.054 μM, oral. Halts VEGFR-2, CK2α, topo IIβ, tubulin. Causes G2/M, pre-G1 arrest, cancer cell death.</p>Formula:C22H15N3O2SColor and Shape:SolidMolecular weight:385.44CPL304110
CAS:<p>CPL304110: oral, selective FGFR 1-3 inhibitor; IC50 - FGFR1: 0.75nM, FGFR2: 0.5nM, FGFR3: 3.05nM.</p>Formula:C25H30N6O2Color and Shape:SolidMolecular weight:446.54EGFR/HER2/CDK9-IN-3
CAS:<p>EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.</p>Formula:C24H21N3O4S2Color and Shape:SolidMolecular weight:479.57EGFR-IN-52
CAS:<p>EGFR-IN-52, a potent EGFR inhibitor, has IC50s: 0.358 μM (wild-type), 86.02 μM (L858R-TK), 432.67 μM (T790M-TK); induces cancer cell apoptosis.</p>Formula:C19H18N4O3SColor and Shape:SolidMolecular weight:382.44UNC-CA359
CAS:<p>UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.</p>Formula:C18H14ClN3O2Color and Shape:SolidMolecular weight:339.78NSC 33994
CAS:<p>NSC 33994 is a selective inhibitor of JAK2 (IC50 = 60 nM). It also shows no effect on Src and TYK2 tyrosine kinase activity at a concentration of 25 μM.</p>Formula:C28H42N2O2Purity:98%Color and Shape:SolidMolecular weight:438.65JAK3/BTK-IN-6
CAS:<p>JAK3/BTK-IN-6: potent BTK (0.6 nM) & JAK3 (0.4 nM) inhibitor, stable in human liver, for blood/immune research.</p>Formula:C21H17BF3N5O3Color and Shape:SolidMolecular weight:455.2EGFR-IN-21
CAS:<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Formula:C36H44BrN10O2PColor and Shape:SolidMolecular weight:759.68BCR-ABL-IN-6
CAS:<p>BCR-ABL-IN-6, an imatinib derivative, inhibits Bcr-AblWT (4.6 nM IC50) and T315I (277 nM), for chronic myeloid leukemia study.</p>Formula:C27H22F3N5O2Color and Shape:SolidMolecular weight:505.49VS 8
CAS:<p>VS 8: potent oral VEGFR-2 inhibitor, anti-angiogenic, induces cancer cell apoptosis & migration, acts on CSCs.</p>Formula:C26H20F3N3O3Color and Shape:SolidMolecular weight:479.45EGFR/HER2-IN-2
CAS:<p>EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).</p>Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49JBJ-09-063 hydrochloride
<p>JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.</p>Formula:C31H30ClFN4O3SColor and Shape:SolidMolecular weight:593.11EGFR-IN-25
CAS:<p>EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.</p>Formula:C34H43N9O2Color and Shape:SolidMolecular weight:609.76EGFR-IN-54
CAS:<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Formula:C17H14N4O4S3Color and Shape:SolidMolecular weight:434.51NSC114792
CAS:<p>NSC114792 is a selective JAK3 inhibitor.</p>Formula:C26H32N4O2SPurity:98%Color and Shape:SolidMolecular weight:464.62SUN13837
CAS:<p>SUN13837, an oral FGFR modulator, crosses the BBB and shows neuroprotective promise.</p>Formula:C21H29N5O2Color and Shape:SolidMolecular weight:383.49TYK2-IN-11
CAS:<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Formula:C18H17N5O3SColor and Shape:SolidMolecular weight:383.42EGFR/HER2-IN-3
CAS:<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49FLT3-IN-18
CAS:<p>FLT3-IN-18: potent, selective FLT3 inhibitor, IC50 0.003 μM, induces apoptosis, G1 arrest, blocks FLT3/STAT5, potential in AML research.</p>Formula:C26H36N8OColor and Shape:SolidMolecular weight:476.62(R)-Elsubrutinib
CAS:<p>(R)-Elsubrutinib ((R)-ABBV-105), a Btk inhibitor, is used in research on immune diseases and cancer.</p>Formula:C17H19N3O2Color and Shape:SolidMolecular weight:297.35EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Formula:C31H37Cl2N7O3SColor and Shape:SolidMolecular weight:658.64VEGFR2 Kinase Inhibitor II
CAS:<p>VEGFR2 kinase inhibitor II: Reversible, cell-permeable, targets VEGFR2 (IC50=70nM), less effective on PDGFRβ (IC50=920nM). Blocks VEGF/PDGF-stimulated growth.</p>Formula:C17H15BrN2OColor and Shape:SolidMolecular weight:343.22
